VCANBIO(600645)2020-10-30 16:00Financial Performance - The company reported operating revenue of RMB 969.37 million for the first nine months of 2020, a decrease of 3.58% compared to the same period last year[18]. - Net profit attributable to shareholders of the listed company reached RMB 133.10 million, an increase of 42.35% year-on-year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 52.73 million, down 26.42% from the previous year[18]. - Total operating revenue for Q3 2020 was CNY 349,874,853.88, a 3% increase from CNY 337,027,026.17 in Q3 2019[53]. - Net profit for Q3 2020 reached CNY 52,393,785.04, compared to CNY 32,194,645.05 in Q3 2019, representing a 62.7% increase[57]. - The total comprehensive income for the first three quarters of 2020 was CNY 133,093,977.65, up from CNY 104,980,318.52 in the same period of 2019[57]. - The total comprehensive income attributable to the parent company's owners for the current period is CNY 23,534,610.23, compared to CNY 35,137,921.60 in the same period last year, reflecting a decrease of approximately 33.5%[60]. - The company reported a net loss of ¥450,885,928.09, an improvement from a loss of ¥583,988,877.39 in the previous period[44]. Assets and Liabilities - The total assets of the company at the end of the reporting period were RMB 5.13 billion, reflecting an increase of 4.85% compared to the end of the previous year[18]. - The company’s total equity attributable to shareholders was RMB 3.61 billion, an increase of 7.77% from the end of the previous year[18]. - Total current assets increased to ¥1,942,380,637.21 as of September 30, 2020, up from ¥1,905,868,878.58 on December 31, 2019, representing a growth of 1.9%[38]. - Total non-current assets reached ¥3,183,407,926.35, compared to ¥2,982,669,581.79, reflecting a growth of 6.7%[42]. - Total liabilities decreased slightly to ¥1,400,241,654.71 from ¥1,427,816,142.75, a reduction of 1.9%[44]. - The total cash and cash equivalents at the end of the period amounted to ¥1,010,203,787.47, compared to ¥990,675,535.57 at the end of the same period last year[71]. Cash Flow - The company generated a net cash flow from operating activities of RMB 151.62 million, a decrease of 3.24% compared to the same period last year[18]. - Net cash flow from investing activities increased by 394.26% compared to the same period last year, mainly due to the recovery of structured deposits[33]. - Net cash flow from financing activities decreased by 120.59% compared to the same period last year, primarily due to the absence of funds raised from a previous equity issuance[33]. - The net cash flow from operating activities for the first three quarters of 2020 was ¥151,618,311.80, a decrease from ¥156,699,220.70 in the same period of 2019[71]. - Cash inflow from investment activities reached ¥1,041,263,969.05, significantly higher than ¥16,764,934.16 in the previous year[71]. - The net cash flow from investment activities was ¥306,040,337.65, a recovery from a negative cash flow of ¥104,003,678.31 in the same period of 2019[71]. - The net cash flow from financing activities was -¥72,575,923.72, contrasting with a positive cash flow of ¥352,456,237.59 in 2019[71]. Shareholder Information - The number of shareholders at the end of the reporting period was 31,827[24]. - Shareholders' equity increased to ¥3,725,546,908.85 from ¥3,460,722,317.62, showing a growth of 7.7%[44]. - Basic earnings per share for the current period is CNY 0.11, an increase from CNY 0.07 in the previous quarter, while diluted earnings per share also stands at CNY 0.11[62]. Investment and Expenses - The company confirmed an investment income of RMB 50.07 million from its U.S. subsidiary's investment in Aceso Biotech Venture Fund, L.P.[27]. - Investment income increased by 527.13% compared to the same period last year, primarily due to the recognition of investment income from subsidiaries[32]. - Research and development expenses for Q3 2020 were CNY 38,377,550.11, a 42.6% increase from CNY 26,913,020.93 in Q3 2019[53]. - The company’s long-term investments in equity decreased to ¥213,491,419.30 from ¥220,661,067.04, a decline of 3.9%[38]. - The cash outflow for purchasing fixed assets and intangible assets was ¥75,168,226.98, an increase from ¥54,658,612.47 in the previous year[71]. Other Financial Metrics - The weighted average return on equity increased to 3.85%, up 0.67 percentage points from the previous year[18]. - Other comprehensive income increased by 326.86% compared to the beginning of the year, mainly due to the recognition of fair value changes of investments[31]. - The company reported a gross profit margin of approximately 13.2% for Q3 2020, compared to 11.5% in Q3 2019[53]. - The company experienced a foreign currency translation loss of CNY -15,800,337.66 in the current period, impacting overall comprehensive income[60]. Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[53]. - The company has not reported any net profit from the merged entity prior to the merger, indicating a focus on future growth opportunities[62]. Accounting Standards - The company implemented new revenue and leasing standards starting January 1, 2020, which are not expected to significantly impact revenue recognition or net profit[76]. - The company did not make retrospective adjustments to prior period financial statements under the new standards[77].